ARS Pharmaceuticals : FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom - Form 8-K

FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom





... | May 9, 2023

Related Keywords

United States ,Harlor Jr ,Camargo Jr ,Epipen ,Adkinson Jr ,Division Of Pulmonology ,Office Of Immunology ,Ars Pk Pd Program Development ,R Joint Task Force On Practice Parameters ,Advisory Committee ,Pediatric Development ,Office Of New Drugs ,Kaleo Inc ,Clinical Pharmacology Development Plan ,While The Division ,Emergency Department ,Drug Administration ,Adamis Pharms Corp ,Impax Labs Inc ,Intranasal Epinephrine Pk Pd Development Program ,Community Settings ,Data On Approved Epinephrine Injection Products ,Pediatric Research Equity ,Second National Institute Of Allergy ,Development Of Other Emergency ,Clinical Program ,Division Or Office ,Clinical Pharmacology Development Program ,Key Aspects Of Development Program ,Pertinent Drug Development ,Anaphylaxis Network ,Administration Issue ,Briefing Document ,Critical Care ,New Drugs ,Drug Evaluation ,Preview Division ,Draft Points ,Brief Description ,Key Aspects ,Development Program ,Key Results ,Clinical Care ,Epinephrine Injection Products ,Regulatory History ,Epinephrine Regulatory History ,Efficacy Issues ,Clinical Pharmacology Summary ,Safety Issues ,Benefit Risk Framework ,Nonclinical Supportive Data ,Nasal Mucosal Damage ,Human Factors ,Human Factors Overview ,Human Factors Discussion ,Pharmacology Development Plan ,Epinephrine Products ,Single Dose ,Intramuscular Injection Using Adrenalin ,Healthy Subjects ,Subjects Who Failed ,Following Two Doses ,Same Naris ,Opposite Naris ,Intramuscular Injection Using Epipen ,Two Doses ,From Baseline ,Following Repeat Doses ,Subjects With Allergic Rhinitis ,Adverse Events Occurring ,Treatment Arm ,Primary Safety Population ,Safety Pooling ,Geometric Mean ,Standard Error ,Concentration Time Profile Following ,Plasma Concentration Time Profiles ,Concentration Time Profile ,Single Dose Epipen ,Single Dose Adrenalin ,Across Studies ,Epinephrine Concentrations ,Time Following ,Concentration Time Profile Following Two Doses ,Subjects With Epinephrine Concentrations ,Greater Following Two Doses ,Predose Nasal Congestion Score ,Subgroup Analysis ,Without Nasal Allergen Challenge ,Nasal Congestion Score Subgroup Analysis ,Plasma Concentration Time Profiles Following ,Staff Administered From ,Self Administered Single Dose ,Pediatric Subjects ,Adult Healthy Subjects From Study ,Blister Pack With ,Nasal Spray Device ,Pharmacology Development Program ,Pharmacology Development ,Unlimited Data ,Approved Epinephrine Injection ,Federal Food ,Cosmetic Act ,Drug Efficacy Study Implementation ,Healthy Volunteers ,Clinical Pharmacology ,Adrenalin Geometric Mean Concentration Time ,Allergen Induced Nasal ,Epinephrine Dosing ,Subjects With Allergic ,Allergen Induced Nasal Congestion ,Pharmacology Review ,Drug Development ,Drugs Act ,Mylan Specialty ,Authorized Generic ,Impax Labs ,Epinephrine Injection ,Pediatric Research Equity Act ,Efficacy Trial ,Cross Discipline Team Leader Review ,Narcan Nasal Spray ,Approved Epinephrine Injection Products ,Bioequivalence Guidance ,Following Repeat ,Without Nasal Allergen ,Time Profiles ,Nasal Congestion Score Subgroup ,After Dosing ,Volunteer Studies ,Risk Framework ,Int Arch Allergy Immunol ,Intensive Care ,Arch Dis Child ,Ann Allergy Asthma Immunol ,Paediatric Exploitation ,Document Step ,Ann Emerg Med ,Fed Proc ,Curr Opin Allergy Clin Immunol ,Biomed Res Int ,Clin Exp Allergy ,Second National Institute ,Food Allergy ,Practice Parameters ,Fatal Anaphylaxis ,Mortality Rate ,Risk Factors ,Adrenergic Agonists ,Pharmacological Basis ,Human Factors Studies ,Related Clinical Study Considerations ,Combination Product Design ,Bioavailability Studies Submitted ,Supportive Data ,Mucosal Damage Changes ,Factors Overview ,Complete Submission ,Threshold Analyses ,Human Factors Submissions ,Current Applicant ,Human Factors Validation Study ,Use Issues Uncovered ,Mitigations Implemented ,Address Use Issues Identified After ,Use Error ,Factors Discussion ,Ars Pharmaceuticals ,Nc Stock Exchange ,News ,Information ,Press Release ,Fda ,Gas ,Osted ,N ,Addendum ,O ,Briefing ,Document ,Its ,Website ,Hat ,Recirculated ,Members ,F ,He Spry Us82835w1080 ,